Multisystem Inflammatory Syndrome in Adults (MIS-A) After COVID-19 Infection and Recent Vaccination with Recombinant Adenoviral Vector Encoding the Spike Protein Antigen of SARS-CoV-2 (ChAdOx1 nCoV-19,Vaxzevria)
Restricted accessCase reportFirst published online February, 2023
Multisystem Inflammatory Syndrome in Adults (MIS-A) After COVID-19 Infection and Recent Vaccination with Recombinant Adenoviral Vector Encoding the Spike Protein Antigen of SARS-CoV-2 (ChAdOx1 nCoV-19,Vaxzevria)
The clinical spectrum of Coronavirus 2019 (COVID-19) includes acute COVID-19, long covid and multisystem inflammatory syndrome in children and adults (MISC/A). The rapid roll-out of COVID-19 vaccination has the potential to affect the clinical presentation of COVID-19 and case reports document rare occurrences of MIS-A after COVID-19 infection and recent vaccination with m-RNA vaccines. We describe 2 cases of MIS-A after COVID-19 infection and recent vaccination with ChAdOx1 nCoV-19.
Zhang YSu XChenW, et al.Epidemiological investigation on a cluster epidemic of COVID-19 in a collective workplace in tianjin. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(5):648-652. doi: 10.3760/cma.j.cn112338-20200219-00121
MasloCFriedlandRToubkinMLaubscherAAkalooTKamaB. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 omicron wave compared with previous waves. JAMA. 2022;327(6):583-584. doi: 10.1001/jama.2021.24868.
4.
MandalSBarnettJBrillSE, et al.‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax [Internet]. 2020;76(4):396‐398. Available from: /pmc/articles/PMC7661378/.
5.
RazzaghiHMartinDNQuesnel-CrooksS, et al.10-year Trends in noncommunicable disease mortality in the Caribbean region. Rev Panam Salud Pública. 2019;43:e37.
6.
CrookHRazaSNowellJYoungMEdisonP. Long COVID-mechanisms, risk factors, and management. Br Med J.2021;374:n1648.
DufortEMKoumansEHChowEJ, et al.Multisystem Inflammatory Syndrome in Children in New York State. https://doi.org/101056/NEJMoa2021756 [Internet]. 2020 Jun 29 [cited 2021 Jul 27];383(4):347–58. Available from: https://www.nejm.org/doi/10.1056/NEJMoa2021756.
9.
DavogusttoGEClarkDEHardisonE, et al.Characteristics Associated With Multisystem Inflammatory Syndrome Among Adults With SARS-CoV-2 Infection. 2021; Available from: https://jamanetwork.com/.
10.
KofmanADSizemoreEKDetelichJFAlbrechtBPiantadosiAL. A young adult with COVID-19 and multisystem inflammatory syndrome in children (MIS-C)-like illness: a case report. Available from: https://doi.org/10.1186/s12879-020-05439-z.
11.
SethuramanNJeremiahSSRyoA. Interpreting diagnostic tests for SARS-CoV-2. JAMA. 2020;323(22):2249‐2251.
YanZ-PYangMLaiC-LCarlos SaizJ. Pharmaceuticals COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. 2021; Available from: https://doi.org/10.3390/ph14050406.
14.
AbobakerARabaAAAboubakerA. Extrapulmonary and atypical clinical presentations of COVID-19. J Med Virol. 2020;92(11):2458‐2464.
15.
LieuAMahJChurchD. A case of multisystem inflammatory syndrome in adults following natural infection and subsequent immunization. International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases. 2022;116:34‐37.
16.
SalzmanMBHuangC-WO’BrienCMCastilloRD. Multisystem inflammatory syndrome after SARS-CoV-2 infection and COVID-19 vaccination - volume 27, number 7—July 2021. Emerging Infectious Diseases Journal - CDC. Emerg Infect Dis [Internet]. 2021;27(7):1944‐1948. Available from: https://wwwnc.cdc.gov/eid/article/27/7/21-0594_article.
17.
UwaydahAKHassanNMMAbu GhoushMSShahinKMM. Adult multisystem inflammatory syndrome in a patient who recovered from COVID-19 postvaccination. BMJ Case Rep. 2021;14(4):e242060. doi:10.1136/bcr-2021-242060
18.
VogelTPTopKAKaratziosC, et al.Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. 2021 [cited 2021 Aug 30];39(22):3037–49. Available from: https://doi.org/10.1016/j.vaccine.2021.01.054.
19.
SawalhaKAbozenahMKadadoAJ, et al.Systematic review of COVID-19 related myocarditis: insights on management and outcome. Cardiovasc Revascularization Med. 2021;23:107‐113. doi:10.1016/j.carrev.2020.08.028
20.
PatoneMMeiXWHandunnetthiL, et al.Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022;28(2):410‐422.
21.
ZhaoJYuanQWangH, et al.Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis [Internet]. 2020;71(16):2027‐2034. Available from: https://pubmed.ncbi.nlm.nih.gov/32221519/.
WHO. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. 2021 [cited 2021 Jul 22]. Available from: https://covid19.who.int/.
24.
MathieuERitchieHOrtiz-OspinaE, et al.Coronavirus pandemic (COVID-19). Our World Data [Internet]. 2020;5(7):947‐953. Available from: https://ourworldindata.org/coronavirus.
